| Literature DB >> 35962235 |
Youhua Liu1,2,3,4, Ying Yang5,6,7, Ruifan Wu1,2,3,4, Chun-Chun Gao5,6,7, Xing Liao1,2,3,4, Xiao Han5,6,7, Botao Zeng1,2,3,4, Chaoqun Huang1,2,3,4, Yaojun Luo1,2,3,4, Yuxi Liu1,2,3,4, Yushi Chen1,2,3,4, Wei Chen1,2,3,4, Jiaqi Liu1,2,3,4, Qin Jiang1,2,3,4, Yuanling Zhao1,2,3,4, Zhen Bi1,2,3,4, Guanqun Guo1,2,3,4, Yongxi Yao1,2,3,4, Yun Xiang8, Xiaojun Zhang8, Teresa G Valencak1, Yizhen Wang1,2,3,4, Xinxia Wang9,10,11,12.
Abstract
Although 5-methylcytosine (m5C) has been identified as a novel and abundant mRNA modification and associated with energy metabolism, its regulation function in adipose tissue and skeletal muscle is still limited. This study aimed at investigating the effect of mRNA m5C on adipogenesis and myogenesis using Jinhua pigs (J), Yorkshire pigs (Y) and their hybrids Yorkshire-Jinhua pigs (YJ). We found that Y grow faster than J and YJ, while fatness-related characteristics observed in Y were lower than those of J and YJ. Besides, total mRNA m5C levels and expression rates of NSUN2 were higher both in backfat layer (BL) and longissimus dorsi muscle (LDM) of Y compared to J and YJ, suggesting that higher mRNA m5C levels positively correlate with lower fat and higher muscle mass. RNA bisulfite sequencing profiling of m5C revealed tissue-specific and dynamic features in pigs. Functionally, hyper-methylated m5C-containing genes were enriched in pathways linked to impaired adipogenesis and enhanced myogenesis. In in vitro, m5C inhibited lipid accumulation and promoted myogenic differentiation. Furthermore, YBX2 and SMO were identified as m5C targets. Mechanistically, YBX2 and SMO mRNAs with m5C modification were recognized and exported into the cytoplasm from the nucleus by ALYREF, thus leading to increased YBX2 and SMO protein expression and thereby inhibiting adipogenesis and promoting myogenesis, respectively. Our work uncovered the critical role of mRNA m5C in regulating adipogenesis and myogenesis via ALYREF-m5C-YBX2 and ALYREF-m5C-SMO manners, providing a potential therapeutic target in the prevention and treatment of obesity, skeletal muscle dysfunction and metabolic disorder diseases.Entities:
Keywords: ALYREF; Adipogenesis; Myogenesis; SMO; YBX2; m5C modification
Mesh:
Substances:
Year: 2022 PMID: 35962235 DOI: 10.1007/s00018-022-04474-0
Source DB: PubMed Journal: Cell Mol Life Sci ISSN: 1420-682X Impact factor: 9.207